# Champions Oncology, Inc.: Form 10-Q for the period ended Jul 31, 2011

- Company: [Champions Oncology, Inc.](/companies/csbr.md) (CIK 771856)
- Form: 10-Q
- Filed: 2011-09-13
- Accepted by EDGAR: Sep 13, 2011, 14:08 ET
- Period: 2011-07-31
- Accession: 0001144204-11-052645
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/771856/000114420411052645/v234451_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/771856/000114420411052645/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-07-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2011-05-01 to 2011-07-31 | $541.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2011-05-01 to 2011-07-31 | −$2.2m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2011-05-01 to 2011-07-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-05-01 to 2011-07-31 | −$2.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-05-01 to 2011-07-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2011-05-01 to 2011-07-31 | −$1.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2011-05-01 to 2011-07-31 | $95.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months, 2011-05-01 to 2011-07-31 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2011-07-31 | $8.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-07-31 | $10.9m | us-gaap:AssetsCurrent |
| Total assets | at 2011-07-31 | $11.8m | us-gaap:Assets |
| Current liabilities | at 2011-07-31 | $3.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-07-31 | $4.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2011-07-31 | −$992.0k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,464 characters.

*The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report.*

### Forward-Looking Statements

This Quarterly Report on Form 10-Q, including Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2011, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

### Overview and Recent Developments

As explained in Item 1, “Business” of our Form 10-K for the year ended April 30, 2011, our operations have recently been refocused to emphasize our Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS) lines of business. We also plan to continue our research and development efforts to expand our Tumorgraft Technology Platform in order to expand our TOS program.

### Operating Results

The following table summarizes our operating results for the periods presented below:

| Operating revenue: | For the Three Months Ended July 31, 2011 | % of Revenue | 2010 | % of% Revenue | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Personalized oncology solutions | $601,000 | 36.8% | $1,109,000 | 69.3% | (45.8)% |
| Translational oncology solutions | 1,033,000 | 63.2 | 491,000 | 30.7 | 110.4 |
| Total operating revenue | 1,634,000 | 100.0 | 1,600,000 | 100.0 | 2.1 |
| **Costs and operating expenses:** |  |  |  |  |  |
| Cost of personalized oncology solutions | 483,000 | 29.6 | 324,000 | 20.3 | 49.1 |
| Cost of translational oncology solutions | 419,000 | 25.6 | 222,000 | 13.9 | 88.7 |
| Research and development | 541,000 | 33.1 | 919,000 | 57.4 | (41.1) |
| Sales and marketing | 688,000 | 42.1 | 134,000 | 8.4 | 413.4 |
| General and administrative | 1,717,000 | 105.1 | 604,000 | 37.8 | 184.3 |
| Total costs and operating expenses | 3,848,000 | 235.5 | 2,203,000 | 137.7 | 74.7 |
| Operating loss | $(2,214,000) | (135.5)% | $(603,000) | (37.7)% | 267.2 |

### Operating Revenues

Operating revenues were $1.6 million for each of the three month periods ended July 31, 2011 and 2010.

Personalized oncology solutions revenues were $0.6 million and $1.1 million for the three months ended July 31, 2011 and 2010, respectively, a decrease of $0.5 million, or 46%. This decrease was the result of the Company’s strategic decision to re-engineer its products to facilitate lower price points which are expected to result in higher volumes. During the quarter, the Company did generate significantly higher volumes, but these were not yet sufficient to overcome the impact of the price decreases. These decreases were partially offset by an increase in gene sequencing revenue over the prior year first quarter.

Translational oncology solutions revenues were $1.0 million and $0.5 million for the three months ended July 31, 2011 and 2010, respectively, an increase of $0.5 million or 110%. The increase in TOS revenues was due primarily to an increase in the number of contracts over the prior year first quarter, driven by the Company’s increased sales efforts.

### Cost of Personalized Oncology Solutions

Cost of POS for the three months ended July 31, 2011 and 2010 was $0.5 million and $0.3 million, respectively, an increase of $0.2 million, or 49%. For the three months ended July 31, 2011 and 2010, gross margins for POS were 20% and 71%, respectively. The decrease in gross margin was due to declines in pricing.

### Cost of Translational Oncology Solutions

Cost of TOS for the three months ended July 31, 2011 and 2010 was $0.4 million and $0.2 million, respectively, an increase of $0.2 million, or 89%. The increase in costs was due to the increased volume of TOS business. For the three months ended July 31, 2011 and 2010, gross margins for TOS were 59% and 55%, respectively.

### Research and Development

Research and development expenses for the three months ended July 31, 2011 and 2010 were $0.5 million and $0.9 million, respectively, a decrease of $0.4 million, or 41%. The decrease from prior year first quarter was primarily related to lower spending on our technology platform and tumorgraft testing on the in-licensed compounds.

### Sales and Marketing

Sales and marketing expenses for the three months ended July 31, 2011 and 2010 were $0.7 million and $0.1 million, respectively, an increase of $0.6 million, or 413%. The increase is primarily related to the increase in Company sales force personnel and increased marketing and promotional expenses.

### General and Administrative

General and administrative expenses for the three months ended July 31, 2011 and 2010 were $1.7 million and $0.6 million, respectively, an increase of $1.1 million, or 184%. The increase is primarily related to an increase in stock-based compensation and an increase in Company personnel due to growth.

### Other Income (Expense)

Other income for the three months ended July 31, 2011 and 2010 was $177,000 and $12,000 respectively, an increase of $165,000. During the three months ended July 31, 2011, the Company recognized income of $177,000 for the change in fair value of warrants that are accounted for as liabilities and are described further below and in Note 5 to the accompanying unaudited condensed consolidated financial statements. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. This change in fair value of warrant liability was a result of revaluing the warrant liability based on the Monte Carlo simulation valuation model, impacted primarily by the quoted price of the Company's common stock. The revaluation of the warrant liability has no impact on our cash balances.

### Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements and other strategic initiatives. In the past, we have met these cash requirements through our cash and cash equivalents, working capital management and proceeds from certain private placements of our securities. As of July 31, 2011, we had working capital of $7.1 million and cash and cash equivalents of $8.8 million. We believe that our cash and cash equivalents on hand at July 31, 2011 are adequate to fund operations for at least the next twelve months.

On March 24, 2011, we entered into a Securities Purchase Agreement with several accredited investors for the sale to the investors of an aggregate 12,533,333 shares of the Company’s common stock at a purchase price of $0.75 per share, or an aggregate of $9,400,000, of which, $500,000 was sold to officers and directors of the Company. As part of this transaction, we issued warrants to purchase an aggregate 1,010,000 shares of common stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date, which occurred on April 4, 2011. The Securities Purchase Agreement contains certain anti-dilution protections for the investors and certain registration rights with respect to the shares of common stock issued to the investors. Furthermore, investors will have the right to require the Company to repurchase the purchased common shares held (the “Put Option”) for cash for $0.75 per share upon a change of control or sale of substantially all of the company’s assets. The Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.

The warrants issued in connection with the Securities Purchase Agreement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its common stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).

The Company has accounted for the warrants issued in connection with the Securities Purchase Agreement as liabilities based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying Condensed Consolidated Balance Sheets, totaled $746,000 at the time of the close of the Securities Purchase Agreement. As of April 30, 2011, the fair value of these warrants increased $36,000 to $782,000. During the quarter ended July 31, 2011, the fair value of these warrants decreased by $177,000 to $794,000. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s Statement of Operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. Changes in the liability from period to period are recorded in the statements of operations under the caption "Change in fair value of warrants."

Due to the Put Option described above, the Company has accounted for the Common Stock issued under the Securities Purchase Agreement as temporary equity, which is reflected under the caption “Redeemable common stock” on the consolidated balance sheet, at April 30, 2011 included in Item 15. The total amount allocated to these common shares was $8,159,000. This allocation is equal to the total proceeds of $9,400,000, less the amount allocated to the warrants of $936,000 and is net of direct and incremental costs associated with the Securities Purchase Agreement of $305,000.

If we require additional cash, there can be no assurance that management will be successful in raising additional capital on terms acceptable to us, if at all. Our ability to successfully complete a raise of capital will depend on the conditions of the capital markets and our financial condition and prospects. Even if we are able to successfully raise additional capital, such capital could be in the form of debt and could be at high interest rates and/or require us to comply with restrictive covenants that limit financial and business activities. In addition, even if we are able to successfully raise equity capital, this could dilute the interest of existing shareholders and/or be issued with preferential liquidation, dividend or voting rights to those currently held by our common stockholders.

### Cash Flows

The following discussion relates to the major components of our cash flows:

#### Cash Flows from Operating Activities

Net cash used in operating activities was $1.5 million and $0.4 million for the three months ended July 31, 2011 and 2010, respectively. The increase of $1.1 million cash used in operations relates to the net loss and the increase in accounts receivable, offset primarily by an increase in stock-based compensation expense.

#### Cash Flows from Investing Activities

Net cash used in investing activities was $95,000 and $20,000 for the three months ended July 31, 2011 and 2010, respectively. Cash used for the quarter ended July 31, 2011 relates to the purchase of property and equipment.

#### Cash Flows from Financing Activities

Net cash provided by financing activities was $4,000 for the three months ended July 31, 2011, due to the exercise of 15,000 warrants. Net cash used in financing activities were $31,000 for the three months ended July 31, 2010, due to the purchase of treasury stock.

### Critical Accounting Estimates and Policies

We believe that of our significant accounting policies, the following may involve a higher degree of judgment and complexity:

### General

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of the consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to areas that require a significant level of judgment or are otherwise subject to an inherent degree of uncertainty. These areas include carrying amounts of long-lived assets and deferred taxes. We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources. Actual amounts could differ significantly from amounts previously estimated.

### Revenue Recognition

We derive revenue from POS and TOS. Personalized oncology solutions assist physicians by providing information that may enhance personalized treatment options for their cancer patients through access to expert medical information panels and tumor specific data. Translational oncology solutions offer a preclinical tumorgraft platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings. We recognize revenue when the following four basic criteria are met: (i) a contract has been entered into with our customers; (ii) delivery has occurred or services have been rendered to our customers; (iii) the fee charged is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured, as fees for services are remitted in full upon execution of the contract. We utilize a proportional performance revenue recognition model for its translational oncology solutions under which we recognize revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to our customers documenting the results of our testing protocols.

When a personalized oncology solution or translational oncology solution arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, (ii) if we have given the customer a general right of return relative to the delivered item(s), and (iii) delivery or performance of the undelivered item(s) or service(s) is probable and substantially in our control. Revenue on multiple element arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement.

### Share-Based Payments

We typically recognize expense for share-based payments based on the fair value of awards on the date of grant. We use the Black-Scholes option pricing model to estimate fair value. The option pricing model requires us to estimate certain key assumptions such as expected life, volatility, risk free interest rates, and dividend yield to determine the fair value of share-based awards. These assumptions are based on historical information and management judgment. We expense share-based payments over the period that the awards are expected to vest, net of estimated forfeitures. If the actual forfeitures differ from management’s estimates, compensation expense is adjusted. We report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows.

### Warrant Liability

Warrant liability represents the fair value of warrants issued in connection with the Securities Purchase Agreement as liabilities based on the certain exercise price reset provisions. The liability, which is recorded at fair value on the accompanying consolidated balance sheet, is calculated by the Monte Carlo simulation valuation method. The change in fair value of these warrants is recognized as other expense in the consolidated statement of operations.

### Research and Development

Research and development costs represent costs incurred internally for research and development activities, costs of licensing drug compounds as well as costs incurred externally to fund research activities. All research and development costs are expensed as incurred. Non-refundable advance payments are capitalized and recorded as expense when the respective product or services are delivered.

### Recently Issued Accounting Pronouncements

See Note 2 of our Notes to Unaudited Condensed Consolidated Financial Statements included in Item 1 of this Form 10-Q.

### Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

## Controls and procedures

As filed, 1,730 characters.

### Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). Our management, with the participation of our Chief Executive Officer and our Acting Principal Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Form 10-Q quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Acting Principal Financial Officer, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Acting Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 124 characters.

There have been no material changes in risk factors previously disclosed in our Form 10-K for the year ended April 30, 2011.

Filed Sep 13, 2011.
Source: SEC EDGAR, the filing index for accession 0001144204-11-052645. Last ingested by Listed: Nov 10, 2026, 03:33 ET. No prices; not investment advice.
